biomed devic servic
biomed devic servic
price close busi juli
kick earn season tuesday morn note large-cap med-tech
group continu trade record level consensu price-to-earnings histor
peak/trough level rel year respect coverag
continu overweight new product cycl recent share pull-back
follow merger specul view snn turnaround name
new ceo begin reshap narr focu execut lastli
remain sidelin given expect quality/suppli issu
continu limit rev/ep upsid next month
thought think estim revenu growth
pro-forma ep growth may prove conserv look continu momentum
mako see focu call
mid/long-term remain opinion one best posit respect
product cycl industri trend near long term well-run firm
med-tech expect share momentum persist
thought comfort estim revenu growth
pro-forma ep growth howev think unlik snn
surpris upsid given softer expect revenu
mid/long-term believ snn strong cadenc new product
differenti play robot navio look new ceo deliv
concentr execut strategi reacceler top/bottom line growth exit
thought comfort estim revenu growth
declin pro-forma ep key focu time progress
mid/long-term current valuat consensu ep estim
surpris long-term investor start opportunist build posit
next six month particularli given manag provid enough forward
inform start piec togeth mosaic howev messag
regard timelin suppli new product turnaround sale momentum
increasingli make feel like late event keep us sidelin
industri data point consid
includ extra sell day posit impact procedur
revenu littl impact capit revenu
includ procedur headwind eu relat bed control due
sever flu season expect procedur recoup
may give larger normal lift typic q/q season
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
biomed devic servic
quick note large-cap medic devic valuat
large-cap medic devic group compris compani current trade
price-to-earnings versu averag forward price-to-earnings consensu
estim within coverag snn trade
consensu price-to-earnings respect overal acknowledg
valuat med-tech space frothi continu believ underli
fundament across industri name procedur volum new product cycl
figur snn forward consensu price-to-earnings
year forwardlarge-cap medic devic grouplarge-cap year year forwardsykzbhsnnlarge-cap year year forwardstryk histor valuationssyksyk year forwardzimm histor valuationszbhzbh year year forwardsmith nephew histor valuationssnnsnn year average biomed devic servic
enter run start given robust new product cycl across
busi unit healthi underli end market fundament
result built upon reinforc thesi continu deliv
msd organ revenu growth take market share across board benefit
meaning halo effect mako placement -- someth expect
continue/acceler throughout note underli new product cycl
medsurg ortho/recon support fundament momentum across
market share ytd bare unforeseen macro event expect
momentum continu despit lofti valuat
consensu ep estim underli fundament busi
unit remain strong earn call next week look addit
commentari mako especi system util expect market
impact competit robot launch next month
thing look for/area focus
mako given mako on-going success share gain increas util
increas competit robot space expect mako remain focu
call specif look sign continu demand
implic orthro share gain potenti pull-through portfolio
product momentum system placement util
continu acceler think investor start wonder momentum
plateau someth think bigger focu given smith nephew
ramp effort navio zimmer soft launch rosa said
result show sign acceler capit rep abl focu
system placement rather upgrad allow place system
competit account continu look commentari
impact total knee applic smith nephew navio surgic
system enter market although unlik impact mako
adopt near-term think system lower cost decreas footprint
could provid compel altern hospit asc
new product launch head print focus earli
traction new product launch newli integr imag tower
novadaq spi fluoresc imag technolog new pivot guardian bed
first post-fre hip distract system next-gen trident ii acetabular hip
system print cup mako compat
merger rumor wsj stori potenti syk/ merger certainli
made fun week wont mid-jun compani quickli
put kibosh storylin least heard
investor felt truth fiction stori may
spook neg market respons share trade nearli
day post wsj stori still havent recov fulli dont expect
manag specif comment rumor expect question
around scale end market exposur focu sell-sid question
call remind recent publish thought syk/bsx could look
like
chang estim
made slight adjust estim reflect updat fx trend
biomed devic servic
addit updat histor revenu build conform
us/ou revenu break-out provid conjunct
previous disclos new account standard adopt
figur summari chang estim
remain posit head print despit weak start
admittedli felt like smith nephew took step backward key object
acceler top-lin growth trade profit expans disappoint tepid/
flat result key segment start year continu think snn
comprehens view differenti product portfolio support market
share gain beyond albeit lesser degre near term
given result convers investor yield mute expect
upsid result come surpris given share trade
month post result said despit near-term volatil
reiter thesi snn track prolong period execut
market share gain growth y/i deliv leverag upsid
support new new ceo/manag team comprehens
except ep newold newold newold revenu operatin net biomed devic servic
snn thing look for/area focus
new ceo namal nawana result call first major investor event
sinc new ceo namal nawana took earli may snn road
day meet mid-may investor keenli focus mr nawana
vision compani strateg chang expect come
year specif investor spoke look better understand smith
nephew long-term growth profil valu could achiev go-
forward basi expect mr nawana use call provid high-level
commentari regard took role opportun snn said
given mr nawana short tenur ceo seat month think unlik
see full strateg updat vision compani move forward asid
exist strategi take share key market reacceler top-lin growth
deliv trade profit expans interact mr
nawana person convers investor overwhelmingli
posit view disciplin alloc capit strong
background commerci experi within orthoped remind mr nawana
replac former ceo olivi bohuon follow announc
plan retir mr nawana bring year med-tech experi
recent serv ceo aler well variou senior leadership
role johnson johnson depuy orthoped busi unit across variou
market includ us apac european market expect learn
mr nawana medium-to-long-term plan snn sometim later
navio expect investor focus navio surgic system given
recent success commerci steal market share
mako navio reach first year market total knee
applic commerci expect market momentum gain steam
dont think manag provid system placement look
commentari regard physician train util exist placement knee
share gain driven specif navio placement remind navio surgic
system compat compani journey ii genesi ii total knee
system previous publish robot deep dive addit detail
apex cost save program recal manag provid full detail
compani new cost save refer apex call program
expect result annual cost save realiz
compani expect incur charg next year
overal program call streamlin manufactur effort improv
effici enhanc commerci effect -- augment
build upon previous plan margin enhanc importantli unlik
previou restructur program manag note apex
impact commerci organ top-lin growth still earli
implement apex look initi commentari execut
cost save initi manag expect save
chang smith nephew estim
made slight adjust estim reflect updat fx trend
incorpor lower expect fx benefit remaind
biomed devic servic
figur summari chang snn estim
head print remain cautiou given uncertainti surround zimmer
on-going manufactur issu impact compani abil recoup lost
market share deliv growth expect come month sum
acknowledg zimmer trade inexpens valuat
consensu earn vs broad large-cap group remain
sidelin look tangibl turnaround busi
thing look for/area focus
manufactur constraint call note fda recent
conclud anoth inspect warsaw manufactur facil result
addit observ addit observ well zbh formal
respons fda releas intra-quart compani continu
make progress remedi effort appear time effort remain
move target said compani continu work consult refin
manufactur process well dual-sourc manufactur key product
conced still possibl although unlik theyv allevi
suppli constraint met previou timelin exit point
except ep newold newold newold revenu breakdownsport trauma wound trade ebitda net pro-forma biomed devic servic
continu think manufactur issu resolv remain cautiou given
uncertainti surround time subsequ cadenc recaptur lost
custom call look updat timelin manufactur
remedi well potenti neg impact compani current
futur sale growth declin
product pipelin recal come zimmer analyst meet aao
confer mr hanson reiter import sever new product launch
help close key gap compani portfolio highlight recent launch
stemless shoulder sidu cementless persona trabecular metal tibia
allow zimmer offer full cementless knee help fill product
portfolio addit manag note recent fda approv next-gen rosa
robot system brain procedur look forward highlight launch
persona revis knee total knee rosa robot platform track limit
releas view pipelin posit howev expect take
least product materi impact top-lin
growth call look commentari impact new product
launch well updat upcom product launch help
fend share loss near-term persona revis rosa robotic-solut
robot aao confer zimmer showcas rosa
robotic-assist surgeri system reiter expect control launch
remind rosa system like imag option
launch allow physician use imag pre-op plan
also function without pre-op imag anoth featur zimmer highlight
consist physician workflow requir addit robot tech
procedur call look updat expect control launch
rosa continu expect rosa product cycl given
sale cycl seen mako
chang zimmer estim
made slight adjust revenu estim reflect updat fx
trend incorpor lower expect fx benefit remaind
addit introduc quarterli estim
updat season ep estim expens relat
on-going quality/suppli issu increas sg spend
pro-forma ep estim reduc
biomed devic servic
figur chang estim
except ep newold newold newold revenu gross operatin ebitda net biomed devic servic
biomed devic servic
biomed devic servic
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
stryker corpor quarterli incom statementcanaccord genuiti kyle except per share good technolog special oper ex chg oper ex chg erest incom incom incom ex one-tim chg incom ex one-tim ep ex one-tim chg ep ex acq relat gross oper ex chg oper ex chg ex net charg net ex one-tim growth oper net incom charg ep charg ep ex acq growth net incom charg ep charg ep ex acq figur stryker forma revenu build
biomed devic servic
stryker corpor revenu mixcanaccord genuiti kyle mix us y/i y/i xfx/x q/q q/q mixdomest figur zimmer biomet hold incom statement
biomed devic servic
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep one-tim ep chg share gener oper rate adjust growth growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth figur smith nephew incom statement
biomed devic servic
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
smith nephew incom statementcanaccord genuiti kyle except per share good oper oper trade tax incom incom ex charg pro-forma trade net growth oper trade oper trade figur smith nephew forma revenu build
biomed devic servic
smith nephew revenu buildcanaccord genuiti kyle medicin trauma wound medicin trauma enabl asd inc clinic wound wound wound wound bioactiv establish growth ratessport medicin trauma enabl asd inc clinic wound wound wound wound bioactiv establish xfx/x acq biomed devic servic
